Canterbury DHB


Anaplastic Large Cell Lymphoma (ALCL)

In This Section



Response to chemotherapy such as CHOP in the ALK+ group is good and up to 70% appear to be cured by this treatment even with advanced disease. In ALK-negative patients the outlook is extremely poor with only 15-30% long term survivors. See Savage KJ, Blood Reviews (2007); 21:201-16 for a review of T cell lymphoma.

About this Canterbury DHB document (5961):

Document Owner:

Peter Ganly (see Who's Who)

Last Reviewed:

December 2021

Next Review:

December 2024


Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 5961